Advanced radioiodine-refractory differentiated thyroid cancer: The sodium iodide symporter and other emerging therapeutic targets

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 10, 2014, Pages 830-842

  Spitzweg, Christine ^a   Bible, Keith C ^b   Hofbauer, Lorenz C ^c   Morris, John C ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAYO CLINIC   (United States)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; AZACITIDINE; B RAF KINASE; BEXAROTENE; CABOZANTINIB; DABRAFENIB; IODINE 131; LENVATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; NOTCH RECEPTOR; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PROTEIN SLC5A5; RADIOACTIVE IODINE; ROMIDEPSIN; ROSIGLITAZONE; SELUMETINIB; SODIUM IODIDE SYMPORTER; SORAFENIB; SUNITINIB; TRAMETINIB; UNCLASSIFIED DRUG; VALPROIC ACID; VANDETANIB; VEMURAFENIB; VORINOSTAT; ANTINEOPLASTIC AGENT; COTRANSPORTER;

ADVANCED CANCER; ADVERSE OUTCOME; ANTIANGIOGENIC ACTIVITY; BLEEDING; CANCER INHIBITION; DIARRHEA; DIFFERENTIATED THYROID CANCER; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EPIGENETICS; FATIGUE; GENE EXPRESSION REGULATION; HUMAN; HYPERTENSION; INHIBITION KINETICS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NAUSEA; NIS GENE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PBF GENE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOIODINE REFRACTORY DIFFERENTIATED THYROID CANCER; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM; THYROID NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IODINE RADIOISOTOPES; SIGNAL TRANSDUCTION; SYMPORTERS; THYROID NEOPLASMS;

EID: 84922268569     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70051-8     Document Type: Review

References (99)

1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214. the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Pacini F, Castagna MG, Brilli L, Pentheroudakis G Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl 7):vii110-vii119. the ESMO Guidelines Working Group.
4. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006, 91:2892-2899.
5. Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001, 86:3327-3335.
6. Spitzweg C, Morris JC The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) 2002, 57:559-574.
7. Xing M Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013, 13:184-199.
8. Haugen BR, Sherman SI Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev 2013, 34:439-455.
9. Xing M, Haugen BR, Schlumberger M Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013, 381:1058-1069.
10. Xing M Gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148:948-953.
11. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012, 91:274-286.
12. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012, 118:1764-1773.
13. Furuya F, Hanover JA, Cheng SY Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor. Proc Natl Acad Sci USA 2006, 103:1780-1785.
14. Saji M, Narahara K, McCarty SK, et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 2011, 30:4307-4315.
15. Woyach JA, Shah MH New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 2009, 16:715-731.
16. Fagin JA, Mitsiades N Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008, 22:955-969.
17. Malaguarnera R, Morcavallo A, Giuliano S, Belfiore A Thyroid cancer development and progression: emerging role of cancer stem cells. Minerva Endocrinol 2012, 37:103-115.
18. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 359:31-42. the Motesanib Thyroid Cancer Study Group.
19. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684.
20. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719.
21. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009, 161:923-931.
22. Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011, 165:315-322.
23. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014, published online April 24. http://dx.doi.org/10.1016/S0140-6736(14)60421-9.
24. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010, 11:962-972. the Endocrine Malignancies Disease Oriented Group, the Mayo Clinic Cancer Centerthe Mayo Clinic Cancer Center, the Mayo Phase 2 Consortiumthe Mayo Phase 2 Consortium.
25. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012, 13:897-905.
26. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010, 16:5260-5268.
27. Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008, 26(suppl). abstr 6025.
28. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008, 26:4708-4713.
29. Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011, 29(suppl). abstr 5503.
30. Cabanillas ME, Brose MS, Ramies DA, Lee Y, Miles D, Sherman SI Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). J Clin Oncol 2012, 30(suppl). abstr 5547.
31. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
32. Kim KB, Cabanillas ME, Lazar AJ, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 2013, 23:1277-1283.
33. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
34. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012, 18:2056-2065.
35. Woyach JA, Kloos RT, Ringel MD, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 2009, 94:164-170.
36. Piekarz R, Luchenko V, Draper D, et al. Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. J Clin Oncol 2008, 26(suppl). abstr 3571.
37. Sherman EJ, Su YB, Lyall A, et al. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid 2013, 23:593-599.
38. Bass MB, Sherman SI, Schlumberger MJ, et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010, 95:5018-5027.
39. Brose MS, Nutting CM, Shong YK, et al. Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase III DECISION trial. European Cancer Congress 2013; Amsterdam; Sept 27-Oct 1. Abstr 3155.
40. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30:134-141.
41. Ball DW, Sherman SI, Jarzab B, et al. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J Clin Oncol 2012, 30(suppl). abstr 5518.
42. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013, 31:3639-3646.
43. Brose M, Cabanillas ME, Cohen EE, et al. An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer (ptc) positive for the BRAF V600 mutation and resistance to radioactive iodine (nct01286753, no25530). European Cancer Congress 2013; Amsterdam; Sept 27-Oct 1. Abstr 28.
44. Marsee DK, Venkateswaran A, Tao H, et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol Chem 2004, 279:43990-43997.
45. Reddi HV, Madde P, Cohen YC, et al. Antitumor Activity of VB-111, a novel antiangiogenic virotherapeutic, in thyroid cancer xenograft mouse models. Genes Cancer 2011, 2:993-995.
46. Sivendran S, Liu Z, Portas LJ, et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012, 38:919-925.
47. Reiners C, Hänscheid H, Luster M, Lassmann M, Verburg FA Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol 2011, 7:589-595.
48. Dai G, Levy O, Carrasco N Cloning and characterization of the thyroid iodide transporter. Nature 1996, 379:458-460.
49. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun 1996, 226:339-345.
50. Smanik PA, Ryu K-Y, Theil KS, Mazzaferri EL, Jhiang SM Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997, 138:3555-3558.
51. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013, 368:623-632.
52. Rothenberg SM, McFadden DG, Palmer E, Daniels GH, Wirth LJ Re-differentiation of radioiodine-refractory BRAFV600E-mutant thyroid carcinoma with dabrafenib: A pilot study. J Clin Oncol 2013, 31(suppl). abstr 6025.
53. Hingorani M, Spitzweg C, Vassaux G, et al. The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets 2010, 10:242-267.
54. Riedel C, Levy O, Carrasco N Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 2001, 276:21458-21463.
55. Wartofsky L, Van Nostrand D Radioiodine treatment of well-differentiated thyroid cancer. Endocrine 2012, 42:506-513.
56. Seidlin SM, Marinelli LD, Oshry E Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc 1946, 132:838-847.
57. Silberstein EB Radioiodine: the classic theranostic agent. Semin Nucl Med 2012, 42:164-170.
58. Mazzaferri EL How beneficial is radioiodine therapy for treating distant metastases from thyroid carcinoma?. Nat Clin Pract Endocrinol Metab 2006, 2:610-611.
59. De Vita G, Zannini M, Cirafici AM, et al. Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth Differ 1998, 9:97-103.
60. Portella G, Vitagliano D, Borselli C, et al. Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol Res 1999, 11:421-427.
61. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007, 92:2840-2843.
62. Knauf JA, Kuroda H, Basu S, Fagin JA RET/PTC-induced dedifferation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 2003, 22:4406-4412.
63. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93:3943-3949.
64. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PI3KCA, and AKT1. Cancer Res 2009, 69:4885-4893.
65. Franco AT, Malaguarnera R, Refetoff S, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 2011, 108:1615-1620.
66. Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 2007, 13:1341-1349.
67. Mitsutake N, Knauf JA, Mitsutake S, Mesa C, Zhang L, Fagin JA Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005, 65:2465-2473.
68. Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011, 121:4700-4711.
69. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M, Santisteban P The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 2006, 13:257-269.
70. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009, 69:8317-8325.
71. Saito T, Endo T, Kawaguchi A, et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 1998, 101:1296-1300.
72. - symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 2001, 86:2697-2700.
73. Stratford AL, Boelaert K, Tannahill LA, et al. Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol Metab 2005, 90:4341-4349.
74. Smith VE, Sharma N, Watkins RJ, et al. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. J Clin Endocrinol Metab 2013, 98:2876-2886.
75. Boelaert K, Smith VE, Stratford AL, et al. PTTG and PBF repress the human sodium iodide symporter. Oncogene 2007, 26:4344-4356.
76. Smith VE, Franklyn JA, McCabe CJ Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake. J Endocrinol 2011, 210:157-163.
77. Smith VE, Read ML, Turnell AS, et al. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci 2009, 122:3393-3402.
78. Read ML, Lewy GD, Fong JC, et al. Proto-oncogene PBF/PTTG1IP regulates thyroid cell growth and represses radioiodide treatment. Cancer Res 2011, 71:6153-6164.
79. García B, Santisteban P PI3K is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression. Mol Endocrinol 2002, 16:342-352.
80. Kogai T, Sajid-Crockett S, Newmarch LS, Liu YY, Brent GA Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J Endocrinol 2008, 199:243-252.
81. Liu YY, Zhang X, Ringel MD, Jhiang SM Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells. Endocr Relat Cancer 2012, 19:291-304.
82. de Souza EC, Padrón AS, Braga WM, et al. MTOR downregulates iodide uptake in thyrocytes. J Endocrinol 2010, 206:113-120.
83. Ferretti E, Tosi E, Po A, et al. Notch signaling is involved in expression of thyrocyte differentiation markers and is down-regulated in thyroid tumors. J Clin Endocrinol Metab 2008, 93:4080-4087.
84. Venkataraman GM, Yatin M, Marcinek R, Ain KB Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab 1999, 84:2449-2457.
85. Xing M, Usadel H, Cohen Y, et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 2003, 63:2316-2321.
86. Furuya F, Shimura H, Suzuki H, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004, 145:2865-2875.
87. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001, 86:3430-3435.
88. Puppin C, D'Aurizio F, D'Elia AV, et al. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 2005, 146:3967-3974.
89. Pugliese M, Fortunati N, Germano A, et al. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells. Thyroid 2013, 23:838-846.
90. Hou P, Bojdani E, Xing M Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab 2010, 95:820-828.
91. Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997, 240:832-838.
92. Simon D, Körber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002, 29:775-782.
93. Handkiewicz-Junak D, Roskosz J, Hasse-Lazar K, et al. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res 2009, 2:8.
94. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 2004, 27:334-339.
95. Liu YY, Stokkel MP, Morreau HA, Pereira AM, Romijn JA, Smit JW Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2008, 68:605-609.
96. Kebebew E, Peng M, Reiff E, et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006, 140:960-966. discussion 966-67.
97. 124I PET/CT imaging. Clin Nucl Med 2012, 37:e47-e52.
98. Rosenbaum-Krumme SJ, Bockisch A, Nagarajah J Pioglitazone therapy in progressive differentiated thyroid carcinoma. Nuklearmedizin 2012, 51:111-115.
99. Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack SG, Hu MI, et al. Survival and efficacy of salvage tyrosine kinase inhibitors (TKIs) after first line sorafenib (Sor) failure in patients with advanced differentiated thyroid cancer (DTC). 83rd Annual Meeting of the American Thyroid Association 2013; San Juan, Puerto Rico; Oct 16-20. Abstr 97.